作者
Grant J Brown,Pablo F. Cañete,Hao Wang,Arti Medhavy,Josiah Bones,Jonathan A. Roco,Yuke He,Yuting Qin,Jean Cappello,Julia I. Ellyard,Katharine Bassett,Qian Shen,Gaétan Burgio,Yaoyuan Zhang,Cynthia Turnbull,Xiangpeng Meng,Phil Wu,Vicky Cho,Lisa A. Miosge,T. Daniel Andrews,Matthew A. Field,Denis Tvorogov,Angel F. Lopez,Jeffrey J. Babon,Cristina Aparicio López,África González‐Murillo,Daniel Clemente Garulo,Virginia Pascual,Tess Levy,Eric J. Mallack,Daniel G. Calame,Timothy Lotze,James R. Lupski,Huihua Ding,Tomalika R. Ullah,Giles Walters,Mark Koina,Matthew Cook,Nan Shen,Carmen de Lucas Collantes,Ben Corry,Michael P. Gantier,Vicki Athanasopoulos,Carola G. Vinuesa
摘要
Although circumstantial evidence supports enhanced Toll-like receptor 7 (TLR7) signalling as a mechanism of human systemic autoimmune disease1-7, evidence of lupus-causing TLR7 gene variants is lacking. Here we describe human systemic lupus erythematosus caused by a TLR7 gain-of-function variant. TLR7 is a sensor of viral RNA8,9 and binds to guanosine10-12. We identified a de novo, previously undescribed missense TLR7Y264H variant in a child with severe lupus and additional variants in other patients with lupus. The TLR7Y264H variant selectively increased sensing of guanosine and 2',3'-cGMP10-12, and was sufficient to cause lupus when introduced into mice. We show that enhanced TLR7 signalling drives aberrant survival of B cell receptor (BCR)-activated B cells, and in a cell-intrinsic manner, accumulation of CD11c+ age-associated B cells and germinal centre B cells. Follicular and extrafollicular helper T cells were also increased but these phenotypes were cell-extrinsic. Deficiency of MyD88 (an adaptor protein downstream of TLR7) rescued autoimmunity, aberrant B cell survival, and all cellular and serological phenotypes. Despite prominent spontaneous germinal-centre formation in Tlr7Y264H mice, autoimmunity was not ameliorated by germinal-centre deficiency, suggesting an extrafollicular origin of pathogenic B cells. We establish the importance of TLR7 and guanosine-containing self-ligands for human lupus pathogenesis, which paves the way for therapeutic TLR7 or MyD88 inhibition.